Evidence-Based Medicine Guidelines
Temozolomide for high grade glioma
Temozolomide for high grade glioma is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Temozolomide for High Grade Glioma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/457734/all/Temozolomide_for_high_grade_glioma.
Temozolomide for high grade glioma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/457734/all/Temozolomide_for_high_grade_glioma. Accessed January 27, 2023.
Temozolomide for high grade glioma. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/457734/all/Temozolomide_for_high_grade_glioma
Temozolomide for High Grade Glioma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 January 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/457734/all/Temozolomide_for_high_grade_glioma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Temozolomide for high grade glioma
ID - 457734
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/457734/all/Temozolomide_for_high_grade_glioma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
